I haven't heard much about sch503034, it seems Schering Plough is keeping a lid on it pretty well. Last I heard it didn't have quite the apparent antiviral effectiveness as VX-950 did when dosed for a short period of time as a monotherapy. But I haven't heard anything more about it in regards to its risks, side effect profile and whether or not it retains its effectiveness longer and better than telaprevir does when dosed with IFN both with and without ribavirin. And another interesting future possibility would be the prospect of combining telaprevir with sch503034 and interferon and/or riba. Probably would have a very bad rash side effect profile with all of those in the mix, but for those lucky enough to avoid that, I'm sure its antiviral performance would be awe inspiring.
Without Googling I don't have the exact information on 50303, however, it was fast-traced by the FDA soon after VX-950 was fast-tracked.
The initial results weren't as dramitic as VX-950...overall there was like a 2+log initial drop in VL in 20 days verus a 4log drop for Vertex. What I did like about Schering's trials is that they are taking geno 1's both naive and non-responders. Vertex only accepted tx naive people in their first trials (Phase 2 now open to non-responders).
I was offered a spot in the 503034 trial and declined because it was 12 months in duration. I'm hoping for something a lot less that will still get me to SVR.
I've written this before that Schering-Plough is a huge pharma company with deep pockets and a lot to lose because they also manufacturer Peg-Intron. It's been uncanny how quiet Schering has been about their trial. It was over a year ago that I was asked to join the trial, so maybe we will see some information come out of the Barcelona meeting.
follow this link there is a great presentation about thisdrug in combination Idenix Pharmacuticals. I think it will be one of the highlights of the meeting
Here is some interesting info. on SCH 503034 and the addition of Ritonavir. It looks promising. I know Vertex gets all the attention but these other up and coming protease inhibitors deserve more focus, particularly since we are seeing some troubling problems with VX in the trials. Let's hope one of them pans out. Maybe SCH503034 will be it. They sure could come up with a better name for it!
Hope you are doing ok and not having too many side effect problems. Hang in there!
thank you for the interesting link. Someday there will be a bundle of different treatments against HCV!
I am doing quite well. Severe pain of the joint of the left hand would drive me crazy, but since I am already crazy, it doesn't matter :-)
I could be wrong, but off top of head, I think VX-950 still holds the record as regards to which PI gets you to non-dectible sooner, and that may be the critcial factor in the end. Vertex trial results will be made public within a month or so and that's what I would base any decision/comparison on. So far, we've just had some anecdotal cases here, but IMO overall it sounds very encouraging.